ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013 – Lyssna här

Avsnitt

Penalization Theory and Practice for Cox Models
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Biomarker-based phase III clinical trial: Real-world experiences
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Saknas det avsnitt?

Klicka här för att uppdatera flödet manuellt.
Estimating effects of time-varying treatments: pitfalls and opportunities
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Evaluating and addressing consistency of the evidence in a network metaanalysis
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Recent developments in updating and extending risk prediction models, the European Randomized Study of Prostate Cancer Risk Calculator
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
From model building to validation and back: a plea for robustness
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Using network meta-analysis for decision making
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Joint longitudinal survival models for prediction of prostate cancer recurrence following radiotherapy
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Adaptive designs for confirmatory clinical trials with treatment selection
18 apr 2019· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Recent developments in updating and extending risk prediction models, the Prostate Cancer Prevention Trial Calculator
29 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
contribution and discussion
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Gene signatures as treatment modifiers in clinical trial
29 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Biomarker-based phase II trial designs
29 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy
29 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Causal search in high-dimensional settings
29 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Assessing mediation through multiple pathways using natural effect models
28 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
The meta-analytic approach to validation of surrogate endpoints
28 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
TBD (on meta-regression)
28 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Two folklores: ridge regression versus the lasso
27 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare
Purposeful penalization of likelihood in small samples
27 aug 2013· ISCB34 - 34th Annual Conference of the International Society for Clinical Biostatistics - Munich, 25-29 August 2013
ISCB 2013
- Titta Titta igen Fortsätt Tittar...
- Titta senare Titta senare

Avsnitt

Penalization Theory and Practice for Cox Models

Biomarker-based phase III clinical trial: Real-world experiences

Estimating effects of time-varying treatments: pitfalls and opportunities

Evaluating and addressing consistency of the evidence in a network metaanalysis

Recent developments in updating and extending risk prediction models, the European Randomized Study of Prostate Cancer Risk Calculator

From model building to validation and back: a plea for robustness

Using network meta-analysis for decision making

Joint longitudinal survival models for prediction of prostate cancer recurrence following radiotherapy

Adaptive designs for confirmatory clinical trials with treatment selection

Recent developments in updating and extending risk prediction models, the Prostate Cancer Prevention Trial Calculator

Gene signatures as treatment modifiers in clinical trial

Biomarker-based phase II trial designs

Utility-Based Dose-Finding with Ordinal Toxicity and Efficacy

Causal search in high-dimensional settings

Assessing mediation through multiple pathways using natural effect models

The meta-analytic approach to validation of surrogate endpoints

TBD (on meta-regression)

Two folklores: ridge regression versus the lasso

Purposeful penalization of likelihood in small samples